Structure Therapeutics releases amylin and GLP-1 program presentation
GPCR•Materials frame obesity market opportunity
Materials framed a large under-treated obesity market, estimating 3 billion people overweight or obese globally versus about 11-13 million on branded anti-obesity drugs.
The presentation also cited rapid uptake of oral GLP-1s in the U.S., estimating more than 1.4 million patients on oral GLP-1 therapy.
Presentation highlights oral obesity pipeline updates
Structure Therapeutics released a presentation outlining updates on its oral obesity pipeline, highlighting ACCG-2671 as an oral amylin candidate.
Slides also flagged progress on aleniglipron, citing completion of the ACCESS 72-week open-label extension and a Phase 3 update.
